- Home
- MANH vs MDGL Comparison
MANH vs MDGL Comparison
Compare MANH & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANH | MDGL |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.5B |
| IPO Year | 1998 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MANH | MDGL |
|---|---|---|
| Price | $258.91 | $431.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $276.00 | ★ $688.94 |
| AVG Volume (30 Days) | ★ 846.6K | 527.0K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | $131,300,000.00 | ★ $180,133,000.00 |
| Revenue This Year | $8.91 | $65.40 |
| Revenue Next Year | $8.03 | $37.72 |
| P/E Ratio | $94.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.06 | $353.54 |
| 52 Week High | $263.47 | $615.00 |
Technical Indicators
Market Signals| Indicator | MANH | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 44.90 |
| Support Level | $125.04 | $416.21 |
| Resistance Level | $263.47 | $553.95 |
| Average True Range (ATR) | 8.50 | 25.14 |
| MACD | 0.44 | 3.20 |
| Stochastic Oscillator | 84.01 | 61.81 |
Price Performance
Historical ComparisonAbout MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.